THC Drug Dronabinol Safely Reduced Agitation in Alzheimer's Patients in Clinical Trial
Dronabinol (synthetic THC) safely and effectively reduced agitation in Alzheimer's patients over 3 weeks, with a medium effect size and no increase in intoxication or cognitive decline.
Quick Facts
What This Study Found
In a 3-week RCT of 75 Alzheimer's patients, dronabinol decreased agitation significantly more than placebo on the Pittsburgh Agitation Scale (effect size 0.53, p=0.015). The NPI-C agitation/aggression measure showed a trend (effect size 0.36, p=0.094). 84% completed the trial. Dronabinol was not associated with greater intoxication, cognitive decline, or adverse events except somnolence.
Key Numbers
75 participants across 5 sites. PAS decline: -0.74/week between arms (p=0.015, effect size 0.53). NPI-C A/A decline: -1.26 (p=0.094, effect size 0.36). 84% completion rate. Target dose: 10 mg/day. 9% Black, 11% Hispanic. No increase in intoxication, falls, or cognitive decline.
How They Did This
Multicenter (5 sites), 3-week, randomized, parallel, double-blind, placebo-controlled trial. Dronabinol titrated up to 10 mg daily in divided doses. 75 participants meeting criteria for agitation of Alzheimer's disease.
Why This Research Matters
Agitation in Alzheimer's is extremely common and distressing, and current treatments have limited effectiveness with serious safety concerns including increased mortality risk. Dronabinol showed clinically meaningful agitation reduction with a favorable safety profile.
The Bigger Picture
This is a landmark trial as the first large randomized study of dronabinol for Alzheimer's agitation. The FDA approved pimavanserin for this indication in 2024, but options remain limited. Dronabinol could become an important addition to the treatment toolkit.
What This Study Doesn't Tell Us
Only 3 weeks duration. Most participants were on concomitant psychotropics. Moderate sample size. One of two primary outcomes did not reach significance. Long-term safety and efficacy unknown.
Questions This Raises
- ?Would longer treatment show sustained or enhanced benefits?
- ?Could dronabinol reduce the need for antipsychotics in Alzheimer's patients?
- ?What is the optimal dose for balancing efficacy and somnolence?
Trust & Context
- Key Stat:
- Effect size 0.53 on agitation with favorable safety
- Evidence Grade:
- Well-designed multicenter double-blind RCT with racially diverse sample, published in American Journal of Geriatric Psychiatry. Moderate sample size but rigorous methodology.
- Study Age:
- 2026 publication of trial conducted 2017-2024.
- Original Title:
- A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.
- Published In:
- The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 34(2), 167-179 (2026)
- Authors:
- Rosenberg, Paul B, Amjad, Halima, Burhanullah, Haroon, Nowrangi, Milap, Vandrey, Ryan, Pierre, Mersania Jn, Outen, John D, Schultz, Meghan, Marano, Christopher, Agronin, Marc, Wilkins, James M, Harper, David, Laffaye, Todd, Reardon, Eilis, Turner, Kathryn, Ozonsi, Rosain, Drury, Mia, Nguyen, Andre, Hasoğlu, Tuna, Cromwell, Julia, Leoutsakos, Jeannie-Marie, Forester, Brent P
- Database ID:
- RTHC-08589
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Can THC help Alzheimer's agitation?
This clinical trial found that dronabinol (synthetic THC) at up to 10 mg/day safely reduced agitation in Alzheimer's patients with a clinically meaningful effect size and no worsening of cognition.
Did patients get "high" from the medication?
No. Dronabinol treatment was not associated with greater intoxication compared to placebo. Somnolence was the only side effect that was more common with the drug.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08589APA
Rosenberg, Paul B; Amjad, Halima; Burhanullah, Haroon; Nowrangi, Milap; Vandrey, Ryan; Pierre, Mersania Jn; Outen, John D; Schultz, Meghan; Marano, Christopher; Agronin, Marc; Wilkins, James M; Harper, David; Laffaye, Todd; Reardon, Eilis; Turner, Kathryn; Ozonsi, Rosain; Drury, Mia; Nguyen, Andre; Hasoğlu, Tuna; Cromwell, Julia; Leoutsakos, Jeannie-Marie; Forester, Brent P. (2026). A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 34(2), 167-179. https://doi.org/10.1016/j.jagp.2025.10.011
MLA
Rosenberg, Paul B, et al. "A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.." The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2026. https://doi.org/10.1016/j.jagp.2025.10.011
RethinkTHC
RethinkTHC Research Database. "A Randomized Controlled Trial of the Safety and Efficacy of ..." RTHC-08589. Retrieved from https://rethinkthc.com/research/rosenberg-2026-a-randomized-controlled-trial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.